Cover Image

In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma: a study from the chronic malignancies working party of the EBMT

Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Beksaç, Meral (Author) , Eikema, Diderik-Jan (Author) , Koster, Linda (Author) , Hulin, Cyrille (Author) , Poiré, Xavier (Author) , Hamladji, Rose-Marie (Author) , Gromek, Tomasz (Author) , Bazarbachi, Ali (Author) , Ozkurt, Zubeyde Nur (Author) , Pabst, Thomas (Author) , Ben Othman, Tarek (Author) , Finke, Jürgen (Author) , Pirogova, Olga (Author) , Wu, Depei (Author) , Hayat, Amjad (Author) , Hilgendorf, Inken (Author) , Tholouli, Eleni (Author) , Wreede, Liesbeth Cornelia de (Author) , Schönland, Stefan (Author) , Garderet, Laurent (Author) , Drozd-Sokolowska, Joanna (Author) , Raj, Kavita (Author) , Hayden, Patrick J. (Author) , Yakoub-Agha, Ibrahim (Author) , McLornan, Donal (Author)
Format: Article (Journal)
Language:English
Published: 31 January 2024
In: Bone marrow transplantation
Year: 2024, Volume: 59, Issue: 4, Pages: 526-533
ISSN:1476-5365
DOI:10.1038/s41409-023-02160-8
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41409-023-02160-8
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41409-023-02160-8
Get full text
Author Notes:Meral Beksac, Diderik-Jan Eikema, Linda Koster, Cyrille Hulin, Xavier Poiré, Rose-Marie Hamladji, Tomasz Gromek, Ali Bazarbachi, Zubeyde Nur Ozkurt, Thomas Pabst, Tarek Ben Othman, Jürgen Finke, Olga Pirogova, Depei Wu, Amjad Hayat, Inken Hilgendorf, Eleni Tholouli, Liesbeth C. de Wreede, Stefan Schönland, Laurent Garderet, Joanna Drozd-Sokolowska, Kavita Raj, Patrick J. Hayden, Ibrahim Yakoub-Agha and Donal P. McLornan
Description
Summary:Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres. Pre-AHCT, compared to Mel200 patients, Vel-Mel patients had similar International Staging System (ISS) scores and cytogenetic risk profiles; a similar proportion had received bortezomib-based induction (85% and 87.3%, respectively) though they were younger with a better performance status. Vel-Mel patients were more likely to achieve CR post-induction (40.6% vs 20.3%, p < 0.001) and by day 100 of AHCT (CR/VGPR: 70.2 % vs. 57.2%, p < 0.001). There was no difference in 3-year PFS (49% vs 46%, p = 0.06) or early post-AHCT mortality. In multivariable analysis, Vel-Mel associated with inferior PFS (HR: 1.69 (1.27-2.25, p < 0.001) and OS (HR:1.46 (1.14-1.86,p = 0.002), similar to negative effects on PFS of advanced ISS (HR:1.56 (1.33-1.83, p < 0.001), high-risk cytogenetics (HR:1.43(1.18-1.74, p < 0.001) and poor post-induction response(<=PR)(HR: 1.43(1.25-1.62, p < 0.001) Overall, despite superior pre- and post-AHCT responses, there was no improvement in PFS or OS following Vel-Mel. This data supports the findings of the smaller prospective IFM study.
Item Description:Gesehen am 01.07.2024
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-023-02160-8

Similar Items